Patients with clonal disease (AA) and progression to sAML (MDS)
| Patient group . | N . | Median age, y (range) . | Clonal evolution of AA . | Progression to sAML . | Median time from diagnosis to clonal evolution, d . |
|---|---|---|---|---|---|
| AA | 14 | 57 (28-75) | 15% (14/93) | NA | 1145 (427-2671) |
| hMDS | 8 | 61 (44-72) | NA | 33% (8/24) | 234 (28-631) |
| Patient group . | N . | Median age, y (range) . | Clonal evolution of AA . | Progression to sAML . | Median time from diagnosis to clonal evolution, d . |
|---|---|---|---|---|---|
| AA | 14 | 57 (28-75) | 15% (14/93) | NA | 1145 (427-2671) |
| hMDS | 8 | 61 (44-72) | NA | 33% (8/24) | 234 (28-631) |
AA indicates aplastic anemia; MDS, myelodysplastic syndrome; hMDS, hypocellular MDS; sAML, secondary acute myeloid leukemia; and NA, not applicable.